Robert W. Baird Issues Positive Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price

Alto Neuroscience (NYSE:ANRO) had its price objective upped by investment analysts at Robert W. Baird from $16.00 to $22.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s target price points to a potential upside of 54.81% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the company. Chardan Capital assumed coverage on Alto Neuroscience in a research report on Monday, September 29th. They set a “buy” rating and a $15.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th. HC Wainwright increased their price target on Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 24th. Finally, Jefferies Financial Group raised their price target on Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Alto Neuroscience currently has an average rating of “Moderate Buy” and a consensus target price of $23.20.

Alto Neuroscience Price Performance

ANRO stock opened at $14.21 on Thursday. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $15.18. The firm has a market capitalization of $384.83 million, a P/E ratio of -5.95 and a beta of 2.90. The company has a fifty day simple moving average of $7.38 and a two-hundred day simple moving average of $4.40. The company has a quick ratio of 18.43, a current ratio of 18.43 and a debt-to-equity ratio of 0.18.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.14. Analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

A number of large investors have recently made changes to their positions in the stock. SCS Capital Management LLC purchased a new stake in Alto Neuroscience in the 1st quarter valued at about $144,000. Nuveen LLC bought a new stake in shares of Alto Neuroscience during the first quarter valued at approximately $302,000. Peapod Lane Capital LLC purchased a new stake in shares of Alto Neuroscience in the second quarter valued at approximately $613,000. AWM Investment Company Inc. boosted its holdings in shares of Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock valued at $1,948,000 after purchasing an additional 214,153 shares during the period. Finally, Citizens Financial Group Inc. RI bought a new position in Alto Neuroscience in the first quarter worth approximately $83,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.